American researchers have initiated trials for a new pharmaceutical compound designated as ENV-308, designed to replicate the physiological effects of intensive physical training. Formulated in tablet form, the medication aims to trigger the body's metabolic responses similar to those experienced during exercise.

Scientists at Enveda utilized the Lac-Phe molecule as the core component for this development. Naturally produced by the body during vigorous exertion, this molecule transmits signals to the brain that suppress appetite and signal satiety.

Preclinical trials conducted on animal models demonstrated significant positive results. The tablets effectively reduced hunger levels and facilitated weight loss while entirely preserving existing muscle mass.

Researchers have successfully completed the first phase of clinical trials, confirming the safety of the drug for human use. Future studies will focus on evaluating the compound's impact on metabolism and exploring its potential combination with established therapeutics such as Ozempic.